Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer

European Urology

Volumn 38, Issue 4, 2000, Pages 380-387

  Okegawa, T ^a   Noda, H ^a   Nutahara, K ^a   Higashihara, E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Complexed prostate specific antigen; Free prostate specific antigen; Prostate cancer

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0033755458     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020312     Document Type: Article

References (31)

1. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
2. Comparison of digital rectal examination and serum prostate specific antigen in the early detection and prostate cancer: Results of a multi-center clinical trial of 6630 men
3. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen
4. Prostate specific antigen density: A mean of distinguishing benign prostatic hypertrophy and prostate cancer
5. Serum prostate specific antigen in a community-based population of healthy man: Establishment of age-specific reference ranges
6. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted of total gland volume (PSAD) in detecting adenocarcinoma of the prostate
7. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
8. Prostate specific antigen density of transition zone a new effective parameter for prostate cancer prediction
9. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
10. 1-antichymotrypsin
11. 1-antichymotrypsin in blood
12. Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex
13. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostares: The best scenario
14. Analysis of percentage free prostatic-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age
15. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostate disease
16. Significance of serum free prostate specific antigen in the screening of prostate cancer
17. Prostate-specific antigen and its complexes with alpha-1-antichymotrypsin in the plasma of patients with prostatic disease
18. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples
19. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
20. Determination of alpha-1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA
21. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
22. 1-antichymotrypsin complex for the screening and management of prostate cancer
23. Measurement of complexed PSA improves specificity for early detection of prostate cancer
24. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia
25. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improve differentiation between benign prostatic hyperplasia and prostate cancer?
26. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
27. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/ml
28. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer
29. 1-antichymotrypsin determination in prostate cancer
30. Determination of prostate volume by a receiver operating characteristics (ROC) curve
31. A method of comparing the areas under receiver operating characteristics curves derived from the same cases